L Cevhertas, I Ogulur, DJ Maurer, D Burla, M Ding… - Allergy, 2020 - Wiley Online Library
In this review, we discuss recent publications on asthma and review the studies that have reported on the different aspects of the prevalence, risk factors and prevention, mechanisms …
Although asthma is very common, affecting 5–10% of the population, the diagnosis of asthma in adults remains a challenge in the real world, which results in both over-and under …
M Kraft, M Richardson, B Hallmark… - The Lancet …, 2022 - thelancet.com
Background Although small airway disease is a feature of asthma, its association with relevant asthma outcomes remains unclear. The ATLANTIS study was designed to identify …
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide, and its prevalence is increasing. Airway inflammation is a consistent …
JC Virchow, P Kuna, P Paggiaro, A Papi, D Singh… - The Lancet, 2019 - thelancet.com
Background To date, no studies have assessed the efficacy of single-inhaler triple therapy in asthma. Here we report on two studies that compared the single-inhaler extrafine …
D Xiao, Z Chen, S Wu, K Huang, J Xu… - The Lancet …, 2020 - thelancet.com
Background Small airway dysfunction is a common but neglected respiratory abnormality. Little is known about its prevalence, risk factors, and prognostic factors in China or anywhere …
M Bonini, M Di Paolo, D Bagnasco… - European …, 2020 - Eur Respiratory Soc
Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a …
Biologics, including omalizumab, mepolizumab, benralizumab, and dupilumab, targeting downstream IgE, cytokines IL-5, and IL-4/13, respectively, have shown promising effects in …
S Nolasco, C Crimi, C Pelaia, A Benfante… - The Journal of Allergy …, 2021 - Elsevier
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) affects around 60% of patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for …